Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Year: 2020
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: The coronavirus disease 2019 (COVID-19) pandemic spread globally in the beginning of 2020. At present, predictors of severe disease and the efficacy of different treatments are not well understood. We conducted a systematic review and meta-analysis of all published studies up to 15 March 2020, which reported COVID-19 clinical features and/or treatment outcomes. Forty-five studies reporting 4203 patients were included. Pooled rates of intensive care unit (ICU) admission, mortality, and acute respiratory distress syndrome (ARDS) were 10.9%, 4.3%, and 18.4%, respectively. On meta-regression, ICU admission was predicted by increased leukocyte count (P < .0001), alanine aminotransferase (P = .024), and aspartate transaminase (P = .0040); elevated lactate dehydrogenase (LDH) (P < .0001); and increased procalcitonin (P < .0001). ARDS was predicted by elevated LDH (P < .0001), while mortality was predicted by increased leukocyte count (P = .0005) and elevated LDH (P < .0001). Treatment with lopinavir-ritonavir showed no significant benefit in mortality and ARDS rates. Corticosteroids were associated with a higher rate of ARDS (P = .0003).
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciaa576
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: COVID-19 pandemic, risk factors for severe disease, treatment efficacy, intensive care unit admission, mortality, acute respiratory distress syndrome, white blood cell count, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, procalcitonin, lopinavir/ritonavir, corticosteroids
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W3024899790
